Asset profile
vunakizumab
Monoclonal antibody
Evidence outlook · registrational
Psoriasis: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT03463187: The study randomized 211 participants across multiple dose groups and included a placebo arm with participants, care providers, investigators, and outcome assessors masked. Its main efficacy endpoint was the clinical PASI 75 response, but no results are posted, so whether the primary endpoint was met cannot be assessed.
Also in development:Psoriatic Arthritis · Phase 3
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.